Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Calendar
NOV. 15, 2024
Ex-Dividend for 12/10 Dividend
DEC. 10, 2024
Dividend Payable
FEB. 11, 2025
Last Earnings
FEB. 21, 2025
Ex-Dividend for 3/10 Dividend
FEB. 23, 2025
Today
MAR. 10, 2025
Dividend Payable
MAY. 8, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End
Recent Royalty Pharma News
Sun. February 23, 2025 4:32 AM EST | marketbeat.com
